Use of acid-suppresive medications in hospitalized patients;Utilización de supresores de la secreción ácida en pacientes hospitalizados

Anales de Medicina Interna

Volumn 19, Issue 11, 2002, Pages 557-560

  Noguerado Asensio, Arturo ^a   Rodriguez Barrientos R ^a   Zelaya Castro, P ^a   Sanchez Sempere A ^a   Antuna Blanco F ^a   Lutz Garcia E ^a   Quintana De La Cruz, R ^a   Estelles Piera F ^a   Alcazar M S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Histamine 2 receptor antagonists; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG INDICATION; DRUG MISUSE; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PNEUMONIA; PRESCRIPTION; RANDOMIZATION; STRESS ULCER; URINARY TRACT INFECTION; WARD;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DRUG UTILIZATION REVIEW; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; PROTON PUMPS; RETROSPECTIVE STUDIES;

EID: 0036859355     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Thors H, Sigurdsson H, Oddsson E, Thjodleifsson B. Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland. Scand J Gastroenterol 1994; 29: 988-94.
2. Zambrana García JL, Martin Escalante MD. Use and abuse of the prescription of anti-ulcer agents. Aten Primaria 2000; 26: 711-2.
3. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 137-43.
4. Erviti J. Multicenter study of prescription-indication of antacids and antiulcer agents in primary care. Aten Primaria 1999; 24: 134-9.
5. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95: 3118-22.
6. Souney PF. Stress ulcer prophylaxis in an evidence-based analysis of therapy. Am J Gastroenterol 1999; 94: 2566-7.
7. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999; 56: 347-79.
8. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997; 54: 581-96.
9. Maton PN, Burton ME. Antacids revisited: A review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855-70.
10. Estruch R, Pedrol E, Castells A, Masanes F, Marrades RM, Urbano-Marquez A. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. Scand J Gastroenterol 1991; 26: 819-26.
11. Gullotta R, Ferraris L, Cortelezzi C, Minoli G, Prada A, Comin U et al.Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. Ital J Gastroenterol Hepatol 1997; 29: 325-9.
12. Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med 1999; 27: 98-103.
13. Carmona-Sánchez R, Suazo-Barahona J, González A, Carmona-Sánchez L, Uscanga-Domínguez L. Use and abuse histamine H2 receptor blockers in hospitalized patients. Rev Gastroenterol Mex 1997; 62: 84-8.
14. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care (Lond) 1999; 3(6): 145-149.
15. Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000; 172: 16-8.
16. Dettmer RM, Riley TH, Byfield F, Green PH. The use of intravenous H2-receptor antagonists in a tertiary care hospital. Am J Gastroenterol 1999; 94: 3473-7.
17. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333-40.
18. Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ. Long term acid suppressing treatment in general practice. BMJ 1994; 308: 827-30.
19. Cook DJ. Stress ulcer prophylaxis: Gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl 1995; 210: 48-52.
20. Kress S, Schilling D, Riemann JF. Concept of stress ulcer prevention. Is re-thinking necessary? Med Klin 1998; 93: 486-91.
21. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275: 308-14.
22. Erstad BL, Camamo JM, Miller MJ, Webber AM, Fortune J. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med 1997; 25: 1678-84.
23. Pitimana-aree S, Forrest D, Brown G, Anis A, Wang XH, Dodek P. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med 1998; 24: 217-23.
24. Devlin JW, Ben-Menachem T, Ulep SK, Peters MJ, Fogel RP, Zarowitz BJ. Stress ulcer prophylaxis in medical ICU patients: Annual utilization in relation to the incidence of endoscopically proven stress ulceration. Ann Pharmacother 1998; 32: 869-74.
25. Conn HO, Poynard T. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619-32.
26. Goldstein JL. Who needs prophylaxis of nonsteroidal anti -inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000; 12 Suppl 1: S11-5.